Holen Sie sich die Stockscreener-App
29.72
2.52%
0.73
Handel nachbörslich:
30.00
0.28
+0.94%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$28.99
Offen:
$28.93
24-Stunden-Volumen:
2.53M
Relative Volume:
1.04
Marktkapitalisierung:
$4.91B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
15.24
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
+3.59%
1M Leistung:
-0.27%
6M Leistung:
+1.26%
1J Leistung:
+1.61%
1-Tages-Spanne:
$28.67
$30.05
1-Wochen-Bereich:
$27.89
$30.05
52-Wochen-Spanne:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Vergleichen Sie ALKS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
29.72 | 4.79B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
127.69 | 56.36B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.52 | 45.81B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.76 | 43.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
26.32 | 28.67B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
488.43 | 20.92B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-11 | Eingeleitet | Truist | Buy |
| 2025-09-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2025-06-17 | Hochstufung | UBS | Neutral → Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Avadel (AVDL) Drops 6.7% on Lack of Leads - Finviz
Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt - Citeline News & Insights
Alkermes (ALKS) Expected to Complete Avadel Acquisition in Early 2026 - GuruFocus
How (ALKS) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Alkermes to Participate in Two Upcoming December 2025 Investor Conferences - BioSpace
Alkermes to Participate in Two Upcoming Investor Conferences - Barchart.com
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN
United StatesGoodwin Advises Avadel Pharmaceuticals On Increased Offer From Alkermes - Mondaq
How Analysts See the Alkermes Story Changing After Acquisition Moves and New Narcolepsy Data - Yahoo Finance
Is Alkermes plc (8AK) stock a fit for income portfoliosRecession Risk & Consistent Growth Stock Picks - newser.com
Alkermes stock rating reiterated at Neutral by H.C. Wainwright - Investing.com Australia
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Finviz
Will Alkermes plc (8AK) stock benefit from mergersWeekly Investment Recap & Community Supported Trade Ideas - newser.com
Is Alkermes plc (8AK) stock good for wealth creation2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com
Is Alkermes plc (8AK) stock among top earnings playsEarnings Risk Summary & Free Weekly Watchlist of Top Performers - newser.com
What momentum indicators show for Alkermes plc stockWeekly Trade Review & Accurate Intraday Trade Tips - newser.com
Will Alkermes plc (8AK) stock benefit from infrastructure billMarket Movers & Growth Focused Stock Pick Reports - newser.com
Applying Elliott Wave Theory to Alkermes plcWeekly Risk Report & Daily Chart Pattern Signals - newser.com
What recovery options are there for Alkermes plcMarket Trend Report & Reliable Entry Point Alerts - newser.com
Alkermes Fires Back In Bidding War With Lundbeck Over Avadel - Citeline News & Insights
Alkermes, Avadel Bump Deal To $2.37B After Alternate Bid - Law360
Avadel Pharmaceuticals agrees to sweetened $2.37B takeover bid from Alkermes amid bidding war - The Business Journals
Alkermes increases offer for Avadel to $21 in cash plus CVR - Investing.com Nigeria
What data driven models say about Alkermes plc’s futureChart Signals & Proven Capital Preservation Tips - newser.com
Risk vs reward if holding onto Alkermes plcQuarterly Portfolio Review & Reliable Volume Spike Trade Alerts - newser.com
ALKS: NT2 study data support flexible orexin dosing, robust safety, and strategic market expansion - TradingView
Alkermes prevails over Lundbeck in Avadel bidding war - Pharmaceutical Technology
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri - Finviz
Avadel board backs Alkermes' higher offer over Lundbeck proposal - Reuters
Avadel Pharmaceuticals Agrees to Alkermes’ Revised Acquisition Offer - PharmExec.com
Alkermes Faces Bidding Battle For Avadel Pharmaceuticals - Finimize
Alkermes Faces Pressure to Secure the Buyout of Avadel After Lundbeck's Unsolicited Bid, RBC Says - MarketScreener
Alkermes escalates bidding war; US biotech risks ‘falling behind’ China - BioPharma Dive
Alkermes Ups Bid for Avadel to $2.37 Billion After Rival Offer - Contract Pharma
H Lundbeck A/S says noted that our offer for acquiring Avadel no longer is considered superior by their board, we are currently considering our options - MarketScreener
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alkermes Plc-Aktie (ALKS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Nov 03 '25 |
Sale |
30.38 |
9,000 |
273,442 |
69,740 |
3.53%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):